Sana Biotechnology (SANA) Cash from Financing Activities (2020 - 2026)

Sana Biotechnology has reported Cash from Financing Activities for 7 years, with the latest figure at -$128000.0 in Q1 2026.

• Quarterly Cash from Financing Activities fell 113.03% year-over-year to -$128000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $127.6 million (up 790.35% YoY) and the FY2025 annual result came in at $128.7 million, down 35.55% from the prior year.
• Cash from Financing Activities retreated to -$128000.0 in Q1 2026 per SANA's latest filing, from $17.6 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $186.4 million in Q1 2024 and troughed at -$128000.0 in Q1 2026.
• A 5-year average of $21.5 million and a median of $1.6 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities soared 78881.78% in 2024, then plunged 113.03% in 2026.
• Over 5 years, Cash from Financing Activities stood at $1.1 million in 2022, then soared by 61.92% to $1.7 million in 2023, then tumbled by 62.57% to $643000.0 in 2024, then jumped by 2644.95% to $17.6 million in 2025, then sank by 100.73% to -$128000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$128000.0, $17.6 million, and $109.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.